None of the 29 investors followed here reported a position in ZBIO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZBIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 17, 2026 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 16.88 per share. | 60K | $1.01M |
| Apr 28, 2026 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 17.62 - 18.02 per share. | 60K | $1.07M |
| Mar 30, 2026 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 18.23 - 19.31 per share. | 54K | $1.02M |
| Mar 30, 2026 | Lu Hongbo BDirector | Purchase at price 20.00 per share. | 75K | $1.50M |
| Mar 30, 2026 | Lu Hongbo BDirector | Purchase at price 18.63 per share. | 3.8K | $70.20K |
| Mar 30, 2026 | Fairmount Funds Management LlcUnknown | Purchase at price 20.00 per share. | 150K | $3.00M |
| Feb 12, 2026 | Allen Patricia LDirector | Purchase at price 23.77 - 26.50 per share. | 19.9K | $499.75K |
| Feb 10, 2026 | Lu Hongbo BDirector | Purchase at price 22.50 per share. | 26K | $584.66K |
| Feb 4, 2026 | Farmer Joseph LPresident | Stock Award(Grant) at price 21.01 per share. | 974 | $20.46K |
| Feb 4, 2026 | Fox Jennifer AChief Financial Officer | Stock Award(Grant) at price 21.01 per share. | 1.6K | $33.45K |
| Feb 1, 2026 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 17.96 per share. | 57K | $1.02M |
| Jan 8, 2026 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 16.30 - 16.55 per share. | 100K | $1.64M |
| Oct 8, 2025 | Enright Patrick G.Director | Purchase at price 27.76 per share. | 117.3K | $3.25M |
| Oct 8, 2025 | Nunn Jason RaleighDirector | Purchase at price 27.76 per share. | 63.2K | $1.75M |
| Oct 8, 2025 | Sr One Capital Management, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 27.76 per share. | 126.3K | $3.51M |
| Oct 6, 2025 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 20.85 per share. | 36.9K | $769.95K |
| Oct 6, 2025 | Lu Hongbo BDirector | Purchase at price 19.00 per share. | 263.2K | $5.00M |
| Oct 6, 2025 | Fairmount Funds Management LlcDirector | Purchase at price 19.00 per share. | 316.2K | $6.01M |
| Feb 17, 2025 | Moulder Leon Oliver Jr.Chief Executive Officer | Purchase at price 6.67 per share. | 25K | $166.75K |
| Feb 6, 2025 | Xiao TingDirector | Purchase at price 7.76 per share. | 10K | $77.60K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -49.4 | 43.4 | -25.8 | -1.2 | -4.8 | 37.9 | 23.9 | 2.8 | -16.6 | -6.7 | −30.7% | ||
| 2025 | -2.1 | -12.6 | 12.7 | 46.6 | -17.8 | 1.8 | 62.1 | 1.8 | 38.8 | 40.8 | 24.3 | -6.5 | +343.3% |
| 2024 | 25.5 | -45.8 | -28.8 | −51.6% |
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Buy / hold / sell counts